Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds gained in its nearly $12 billion acquisition of Kite Pharma Inc.

The

Read the full 466 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE